

REFERENCES

- American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. *Am J Respir Crit Care Med.* 2000;161:646-664.
- American Thoracic Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. *Am J Respir Crit Care Med.* 2002;165:277-304.
- Antoniou KM, Nicholson AG, Dimadi M, et al. Long-term clinical effects of IFN γ -1b and colchicine in idiopathic pulmonary fibrosis. *Eur Respir J.* 2006;28:496-504.
- Antoniou SA. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. *Expert Opin Investig Drugs.* 2006;15:823-828.
- Chang AC, Yee J, Orringer MB, Lannettoni MD. Diagnostic thoracoscopic lung biopsy: an outpatient experience. *Ann Thorac Surg.* 2002;74:1942-1946.
- Clinical Studies Assessing Pirfenidone in IPF: Research of Efficacy and Safety Outcomes. InterMune, Inc. Web site. 2006. Available at: <http://www.capacitytrials.com>. Accessed March 2007.
- ClinicalTrials.gov. National Institutes of Health and National Library of Medicine Web site. Available at: <http://clinicaltrials.gov/ct/action/GetStudy>. Accessed March 2007.
- Coke M, Edwards LB. Current status of thoracic organ transplantation and allocation in the United States. *Clin Transpl.* 2004;17-26.
- Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2003;168:538-542.
- Collard HR, Ryu JH, Douglas WW, et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. *Chest.* 2004;125:2169-2174.
- Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. *N Engl J Med.* 2005;353:2229-2242.
- Dempsey OJ. Clinical review: idiopathic pulmonary fibrosis—past, present and future. *Respir Med.* 2006;100:1871-1885.
- Egan TM, Murray S, Bustami RT, et al. Development of the new lung allocation system in the United States. *Am J Transplant.* 2006;6:1212-1227.
- Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. *Am J Respir Crit Care Med.* 2003;168:543-548.
- Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. *Thorax.* 2003;58:143-148.
- Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. *Am J Respir Crit Care Med.* 2001;164:1722-1727.
- French CT, Fletcher KE, Irwin RS. Gender differences in health-related quality of life in patients complaining of chronic cough. *Chest.* 2004;125:482-488.
- French CT, Irwin RS, Fletcher KE, Adams TM. Evaluation of cough-specific quality-of-life questionnaire. *Chest.* 2002;121:1123-1231.
- Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2001;164:193-196.



INSPIRE. InterMune Web site. 2007. Available at: <http://www.inspiretrial.com>. Accessed March 2007.

InterMune, Inc. Data on file.

Irwin RS, Boulet LP, Cloutier MM, et al. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. *Chest*. 1998;114(2 Suppl Managing):S133-S181.

Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. *Am J Respir Crit Care Med*. 2005;171:639-644.

Khalil N, O'Connor R. Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. *CMAJ*. 2004;171:153-160.

Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. *Proc Am Thoracic Soc*. 2006;3:285-292.

King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon- γ 1b for idiopathic pulmonary fibrosis. *Chest*. 2005;127:171-177.

Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. *Chest*. 2005;128:1475-1482.

Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. *Am J Respir Crit Care Med*. 2003;168:1084-1090.

Latsi PI, de Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. *Am J Respir Crit Care Med*. 2003;168:531-537.

Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. *Chest*. 2006;129:746-752.

Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. *Am J Respir Crit Care Med*. 2005;172:488-493.

Lynch DA, Travis WD, Muller NL, et al. Idiopathic interstitial pneumonias: CT features. *Radiology*. 2005;236:10-21.

Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. *Ann Intern Med*. 2005;142:963-967.

Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. *Am J Respir Crit Care Med* Articles in Press. Published on January 25, 2007 as doi:10.1164/rccm.200608-1153CC.

Noble PW. Idiopathic pulmonary fibrosis. New insights into classification and pathogenesis usher in a new era of therapeutic approaches. *Am J Respir Cell Mol Biol*. 2003;29(3 Suppl):S27-S31.

Noble PW, Homer RJ. Idiopathic pulmonary fibrosis: new insights into pathogenesis. *Clin Chest Med*. 2004;25:749-758.

Noble PW, Morris DG. Time will tell: predicting survival in idiopathic interstitial pneumonia. *Am J Respir Crit Care Med*. 2003;168:510-511.

O'Callaghan D, Gaine SP. Bosentan: a novel agent for the treatment of pulmonary arterial hypertension. *Int J Clin Pract*. 2004;58:69-73.

Orens JB, Kazerooni EA, Martinez FJ, et al. The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy. A prospective study. *Chest*. 1995;108:109-115.

Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. *N Engl J Med*. 2004;350:125-133.

Raghu G, Chang J. Idiopathic pulmonary fibrosis: current trends in management. *Clin Chest Med*. 2004;25:621-636.

Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2006;174:810-816.

Rena O, Casadio C, Leo F, et al. Videothoroscopic lung biopsy in the diagnosis of interstitial lung disease. *Eur J Cardiothorac Surg*. 1999;16:624-627.

Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP 3rd. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. *Drugs*. 2004;64:405-430.

Strollo DC. Imaging of idiopathic interstitial lung diseases. Concepts and conundrums. *Am J Respir Cell Mol Biol*. 2003;29(3 Suppl):S10-S18.

Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ. Mechanisms of pulmonary fibrosis. *Annu Rev Med*. 2004;55:395-417.

Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplant report—2006. *J Heart Lung Transplant*. 2006;25:880-892.

United Network for Organ Sharing Web site. 2007. Available at: <http://www.unos.org>. Accessed February 2007.

Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. *Proc Am Thorac Soc*. 2006;3:330-338.

Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. *N Engl J Med*. 1999;341:1264-1269.